title: Feasibility and safety of percutaneous coronary intervention in patients with end-stage liver disease referred for liver transplantation.
abstract: Percutaneous coronary intervention (PCI) has traditionally not been an option for patients with end-stage liver disease (ESLD) and coronary artery disease (CAD). This retrospective study was designed to demonstrate the feasibility and safety of PCI in liver transplant candidates. Patients with ESLD and hemodynamically significant CAD who were otherwise deemed to be acceptable candidates for liver transplantation underwent PCI. The procedural success rates, mortality and myocardial infarction rates, and bleeding outcomes were examined. Sixteen patients with ESLD underwent PCI: 15 with bare-metal stents (1.3 stents per patient on average) and 1 with balloon angioplasty alone. The median diameter stenosis per lesion was 80%, the median platelet count was 68 × 10(9) /L, the median international normalized ratio was 1.3, and the median Model for End-Stage Liver Disease score was 13. PCI was successful in 94% of the patients. One patient had a suboptimal residual stenosis of 50% after stenting. There were no in-hospital or 30-day deaths or myocardial infarctions, and no patients developed hematomas. One patient required a 1-U platelet transfusion, and another required 1 U of packed red blood cells. All patients remained clinically stable 1 month after PCI. Nine of the 16 patients were listed for liver transplantation, and 3 patients underwent liver transplantation. In conclusion, we have demonstrated the safety and feasibility of PCI in a small cohort of patients with ESLD and hemodynamically significant CAD, the majority of whom had significant thrombocytopenia. Larger studies are required to determine whether PCI is an effective treatment strategy for patients with ESLD and hemodynamically significant CAD who otherwise would not be candidates for liver transplantation.
authors.affiliation: Cedars-Sinai Heart Institute/California Heart Center, Cedars-Sinai Medical Center, Los Angeles, CA 90211, USA. azarbalb@cshs.org
authors.forename: Babak
authors.initials: B
authors.lastname: Azarbal
authors.forename: Paul
authors.initials: P
authors.lastname: Poommipanit
authors.forename: Boris
authors.initials: B
authors.lastname: Arbit
authors.forename: Antoine
authors.initials: A
authors.lastname: Hage
authors.forename: Jignesh
authors.initials: J
authors.lastname: Patel
authors.forename: Michelle
authors.initials: M
authors.lastname: Kittleson
authors.forename: Saibal
authors.initials: S
authors.lastname: Kar
authors.forename: Fady M
authors.initials: FM
authors.lastname: Kaldas
authors.forename: Ronald W
authors.initials: RW
authors.lastname: Busuttil
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D058625:End Stage Liver Disease / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D019934:International Normalized Ratio; D016031:Liver Transplantation / Q000379:methods*; D008297:Male; D008875:Middle Aged; D061214:Patient Safety; D011379:Prognosis; D015607:Stents; D013921:Thrombocytopenia / Q000097:blood; D016896:Treatment Outcome